Skip to main content
Premium Trial:

Request an Annual Quote

CollabRx, Sengenics Partner on Cancer Diagnostics

NEW YORK (GenomeWeb News) – CollabRx today announced a deal with Sengenics to incorporate each other's products into molecular diagnostics tests and reports aimed at cancer.

Under the terms of the agreement, Sengenics will integrate CollabRx's interpretive content resources into its cancer exome sequencing tests and reports. The combined products are being designed "to seamlessly pair test results with clinically actionable and dynamically updated knowledge on the clinical impact of specific tumor genetic profiles and associated therapeutic strategies, such as drugs and clinical trials," CollabRx said.

The San Francisco-based data analytics firm added that it will provide content in a software-as-a-service-based business model.

The deal, CollabRx said, extends its presence into three continents: North America, Europe, and Asia. Financial and other terms of the agreement were not disclosed.

Today's announcement follows a test and medical information development partnership between CollabRx and OncoDNA that was announced last week.

Based in Kuala Lumpur, Malaysia, Sengenics offers genomics- and proteomics-based diagnostics.

"Our joint solution's ability to provide insights from CollabRx's clinical practitioner network represents critical and timely value to physicians when they are interpreting test results," Arif Anwar, executive director of Sengenics, said in a statement.

The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.